The role of BAFF in lupus pathogenesis is further underscored by the approval of selective biologic therapies, such as Rituximab (anti-CD20) and Belimumab (anti-BAFF) which are two overexpressed cytokines, alongside traditional treatments like NSAIDs and DMARDs (3, 6). The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.